Seek Returns

RPRX vs. ZTS: Royalty Pharma vs. Zoetis Stock Comparison

How do Royalty Pharma (RPRX) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Royalty Pharma (RPRX) and Zoetis (ZTS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Royalty Pharma (RPRX) and Zoetis (ZTS)
Profile ItemRPRXZTS
NameRoyalty Pharma plc Class A Ordinary SharesZoetis Inc. Class A Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticalsPharmaceuticals
GICS Sub-IndustryPharmaceuticalsPharmaceuticals
Market Capitalization38.70 billion USD32.26 billion USD
CurrencyUSDUSD
ExchangeNasdaqNYSE
Listing DateJune 16, 2020February 1, 2013
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

RPRX
ZTS
GSPC
Loading price history…
Royalty Pharma (RPRX) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Royalty Pharma (RPRX) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Royalty Pharma (RPRX) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Royalty Pharma (RPRX) and Zoetis (ZTS)
MetricRPRXZTS
Total Return (1Y)81.08%-30.10%
Total Return (3Y, Annualized)39.21%-20.42%
Total Return (5Y, Annualized)14.22%-16.87%

Risk Profile

Drawdown History

RPRX
ZTS
GSPC
Loading price history…
Royalty Pharma (RPRX) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Royalty Pharma (RPRX) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Royalty Pharma (RPRX) and Zoetis (ZTS)
MetricRPRXZTS
Volatility (1Y, Annualized)22.05%38.23%
Beta (5Y)0.360.66
Max Drawdown (5Y)-41.98%-70.45%
Avg. Volume (3M)3.10M4.65M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
RPRX and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Royalty Pharma (RPRX) and Zoetis (ZTS)
MetricRPRXZTS
Sharpe Ratio (1Y)3.48-0.90
Sortino Ratio (1Y)5.72-1.10

Profitability

ROE (TTM)

Both Royalty Pharma (RPRX) at 12.09% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

12.09%

Max
109.18%
RPRX
12.09%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max
109.18%
ZTS
57.63%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Royalty Pharma (RPRX) at 25.70% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.70%

RPRX
25.70%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS
26.41%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Royalty Pharma (RPRX) at 81.32% and Zoetis (ZTS) at 38.19% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.32%

Max
83.12%
RPRX
81.32%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max
83.12%
ZTS
38.19%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Royalty Pharma (RPRX) and Zoetis (ZTS)
MetricRPRXZTS
ROE (TTM)12.09%57.63%
ROA (TTM)5.43%14.87%
Net Margin (TTM)25.70%26.41%
Operating Margin (TTM)81.32%38.19%
Gross Margin (TTM)99.79%71.65%

Growth

Revenue Growth

Both Royalty Pharma (RPRX) at 5.06% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Royalty Pharma (RPRX) at 23.09% and Zoetis (ZTS) at 10.05% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Royalty Pharma (RPRX) and Zoetis (ZTS)
MetricRPRXZTS
Revenue Growth (YoY)5.06%2.28%
Revenue Growth (3Y CAGR)2.06%5.42%
EPS Growth (YoY)23.09%10.05%
EPS Growth (3Y CAGR)161.10%10.27%

Financial Strength

Current Ratio (MRQ)

Both Royalty Pharma (RPRX) at 1.29 and Zoetis (ZTS) at 2.35 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.29

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
RPRX
1.29
Min
0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ZTS
2.35
Min
0.10
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both balance sheets lean debt-heavy versus peers, but ZTS is more stretched: Royalty Pharma (RPRX) at 0.88 sits in the higher-leverage quartile and Zoetis (ZTS) at 2.80 is above its industry benchmark range.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.88

Max
1.42
RPRX
0.88
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS
2.80
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Royalty Pharma (RPRX) and Zoetis (ZTS)
MetricRPRXZTS
Current Ratio (MRQ)1.292.35
Debt / Equity (MRQ)0.882.80
Net Debt / EBITDA4.761.92

Dividends

Dividend Yield (TTM)

Both Royalty Pharma (RPRX) at 1.37% and Zoetis (ZTS) at 2.55% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.37%

RPRX
1.37%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS
2.55%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Royalty Pharma (RPRX) at 60.46% and Zoetis (ZTS) at 35.24% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

60.46%

RPRX
60.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS
35.24%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Royalty Pharma (RPRX) and Zoetis (ZTS)
MetricRPRXZTS
Dividend Yield (TTM)1.37%2.55%
Dividend Payout Ratio (TTM)60.46%35.24%

Valuation

P/E Ratio (TTM)

Zoetis (ZTS) at 13.50 is near its industry’s usual P/E ratio, while Royalty Pharma (RPRX) at 43.99 sits in the richer quartile — RPRX needs stronger growth or earnings quality to justify the premium.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.99

Max
85.34
RPRX
43.99
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max
85.34
Q3
43.46
Median
26.69
ZTS
13.50
Q1
13.30
Min
0.07
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Royalty Pharma (RPRX) at 14.79 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.79

Max
58.18
Q3
25.77
RPRX
14.79
Median
7.30
Q1
3.01
Min
0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max
58.18
Q3
25.77
Median
7.30
ZTS
3.40
Q1
3.01
Min
0.01
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Royalty Pharma (RPRX) at 4.39 is valued about in line with its industry on P/B ratio, while Zoetis (ZTS) at 9.80 carries an above-peer premium to book — ZTS is pricier on assets.

RPRX

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.39

Max
13.53
Q3
6.54
RPRX
4.39
Median
3.25
Q1
1.69
Min
-5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max
13.53
ZTS
9.80
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Royalty Pharma (RPRX) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Royalty Pharma (RPRX) and Zoetis (ZTS)
MetricRPRXZTS
P/E Ratio (TTM)43.9913.50
P/S Ratio (TTM)14.793.40
P/B Ratio (MRQ)4.399.80
Free Cash Flow Yield (TTM)-1.16%6.36%